-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

636.P1.67 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster I

Myelodysplastic Syndromes – Basic and Translational Studies Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 5, 2015: 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Maitri Shah, MS1, Valentina Pilecki2*, Roxana Redis2*, Linda Fabris2*, Maria Ciccone, MD3,4*, Cristina Ivan2*, Ioana Berindan-Neago2*, Riccardo Fodde5*, Carlos E. Bueso-Ramos, MD6, Mihai Gagea2*, Guillermo Garcia Manero2* and George Calin, MD PhD1

1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
2University of Texas M D Anderson Cancer Center, Houston, TX
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Hematology Section, Azienda Ospedaliero-Universitaria S. Anna, University of Ferrara, Ferrara, Italy
5Erasmus MC, Rotterdam, Netherlands
6The University of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston

Maria E. Balasis1*, Jane Merelvede2*, Sateesh Kunigal1*, Xiaoyi Ren1*, Yan Ma1*, Qing Zhang, PhD1*, Jeff Painter1*, Nathalie M. Droin, PhD2*, Joseph Johnson1*, Sean Yoder, M.S3*, Rami S. Komrokji, MD1, Ling Zhang, MD4, Sheng Wei, MD1, Torsten Haferlach5, Robert MacLeod, PhD6*, Alan F. List, MD7, Eric Solary, MD, Prof2*, P.K. Epling-Burnette, PhD1 and Eric Padron, MD1

1H. Lee Moffitt Cancer Center, Tampa, FL
2Gustave Roussy, Villejuif, France
3Molecular Genomics Core Facility, Moffit Cancer Center and Research Institute, Tampa, FL
4Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
5MLL Munich Leukemia Laboratory, Munich, Germany
6Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, CA
7Department of Hematologic Malignancies, Moffitt Cancer Center and Research Institute, Tampa, FL

Marcio Andrade-Campos, MD1,2*, Marta Andres-Coduras, PhD.3*, Fernando Ramos, MD, PhD, MPH4* and Pilar Giraldo, PhD5

1CIBERER, Carlos III Institute. CIBER Enfermedades Raras, Zaragoza, Spain
2Traslational Research Unit, Instituto Investigación Sanitaria Aragón, Zaragoza, Spain
3Aragon Health Research Institute (IIS-A), Translational Research Unit., Zaragoza, Spain
4Hospital Universitario de León, León, Spain
5Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spanish Foundation for the Study and Therapy of Gaucher Disease (FEETEG), Aragon Institute of Health Sciences (IACS), Zaragoza, Spain

Silvia Buonamici, PhD1, Rachel Darman, PhD1*, Samantha Perino, BS1*, Anant Agrawal, PhD1*, Shouyong Peng, PhD1*, Michael Seiler, PhD1*, Kian Huat Lim, PhD1*, Erica B. Bhavsar2*, Jacob Feala, PhD1*, Esther A. Obeng, MD, PhD3, Suzanna Bailey, PhD1*, Betty Chan, PhD1*, Peter Fekkes, PhD1*, Gregg F. Keaney, PhD1*, Pavan Kumar, PhD1*, Kaiko Kunii1*, Linda Lee, MS1*, Crystal Mackenzie4*, Mark Matijevic4*, Yoshiharu Mizui, PhD1*, Khin Myint4*, Eunice Park1*, Ermira Pazolli1*, Michael Thomas1*, John Wang1*, Markus Warmuth, MD1*, Lihua Yu, PhD1*, Ping Zhu1*, Richard R. Furman, MD5, Benjamin L Ebert, MD, PhD6 and Peter G Smith, PhD1*

1H3 Biomedicine, Cambridge, MA
2Department of Hematology/Oncology, Weill Cornell Medical College, New York, NY
3Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA
4Eisai, Andover, MA
5New York-Presbyterian/Weill Cornell Medical Center, New York, NY
6Division of Hematology, Brigham and Women's Hospital, Boston, MA

Christopher N Hahn, PhD1,2,3*, Milena Babic, BMPharBio (Hons)1,2*, Andreas W Schreiber, PhD4*, Monika M Kutyna, MSc5*, L Amilia Wee, BSc (Hons)5*, Anna L Brown, PhD1,2,5, Michelle Perugini, PhD5*, Deepak Singhal, MD, FRCPA6*, Smita Hiwase, PhD5*, Jinghua Feng, PhD4*, Wendy T Parker, PhD2,4, Sarah Moore, BSc (Hon), FFSc (RCPA)2*, Peter G Bardy, MBBS, FRACP, FRCPA7*, Russell Saal, MMSc, BSMedTech8,9*, Paula Marlton, MBBS, FRACP, FRCPA10,11,12, Andrew S. Moore, MBBS, FRACP, PhD8,10,12,13, Thomas J Gonda, PhD14, Paul Leo, PhD15*, Susan Branford, PhD2, Richard J D'Andrea, PhD1,5,16, Ian D Lewis, MBBS, PhD, FRACP, FRCPA5, Luen Bik To, MBBS, PhD5, Hamish S Scott, BSc, PhD, FFSc (RCPA)1,2,3,17,18,19 and Devendra Hiwase, MBBS, FRACP, FRCPA, MD, PhD5

1Centre for Cancer Biology, SA Pathology & University of South Australia, Adelaide, Australia
2Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia
3School of Medicine, University of Adelaide, Adelaide, Australia
4Centre for Cancer Biology, ACRF Cancer Genomics Facility, SA Pathology, Adelaide, Australia
5Haematology, SA Pathology, Adelaide, Australia
6Haematology, Royal Adelaide Hospital, Adelaide, Australia
7Haematology/Oncology, The Queen Elizabeth Hospital, Woodville, Australia
8Translational Research Institute, Brisbane, Australia
9The University of Queensland Diamantina Institute, The University of Queensland, Brisbane, Australia
10UQ Child Health Research Centre, The University of Queensland, Brisbane, Australia
11Australasian Leukaemia and Lymphoma Group Tissue Bank, Princess Alexandra Hospital, Brisbane, Australia
12Queensland Children’s Cancer Centre and Queensland Children’s Medical Research Institute, Children’s Health Queensland Hospital and Health Service, Brisbane, Australia
13The University of Queensland Diamantina Institute, Brisbane, Australia
14School of Pharmacy, University of Queensland, Woolloongabba, Australia
15Faculty of Medicine and Biomedical Sciences, The University of Queensland Diamantina Institute, Woolloongabba, Australia
16School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Adelaide, Australia
17School of Molecular and Biological Sciences, University of Adelaide, Adelaide, Australia
18Centre for Cancer Biology, University of South Australia, Adelaide, Australia
19ACRF Cancer Genomics Facility, SA Pathology, Centre for Cancer Biology, Adelaide, Australia

Aziz Nazha, MD1, Manja Meggendorfer, PhD2*, Niroshan Nadarajah, M.Sc.2*, Kassy E Kneen3*, Tomas Radivoyevitch, PhD4*, Bartlomiej Przychodzen, MSc5*, Hideki Makishima, MD, Ph.D.6, Bhumika J. Patel7*, Srinivasa R. Sanikommu, MBBS8, Sean Hobson9*, Mridul Mukherji, PhD10*, Mikkael A. Sekeres, MD, MS11, Torsten Haferlach2 and Jaroslaw P. Maciejewski, MD, Ph.D.7

1Leukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
2MLL Munich Leukemia Laboratory, Munich, Germany
3Department of Translational Hematology, Cleveland Clinic, Taussig Cancer Institute, Cleveland
4Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
5Haematological Medicine, Department of Translational hematology and Oncology Research, Taussing Cancer Institute, Cleveland Clinic, London, United Kingdom
6Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
7Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8Cleveland Clinic Taussing Cancer Institute, Cleveland, OH
9Department of Translational Hematology and Oncology Research, Taussing Cancer Institute, Cleveland Clinic, Cleveland, OH
10UMKC School of Pharmacy, Kansas City
11Leukemia Program, Cleveland Clinic, Cleveland, OH

Constance Regina Baer, PhD1*, Niroshan Nadarajah, M.Sc.1*, Yasunobu Nagata, MD2*, Tamara Alpermann1*, Genta Nagae, MD, PhD3*, Yusuke Okuno, MD, Ph.D.4*, Yuichi Shiraishi, MD, Ph.D.5*, Satoru Miyano, MD, Ph.D.5*, Claudia Haferlach, MD1, Wolfgang Kern, MD1, Hiroyuki Aburatani, MD, PhD3*, Seishi Ogawa, MD, Ph.D.2 and Torsten Haferlach1

1MLL Munich Leukemia Laboratory, Munich, Germany
2Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
4Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
5Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Valeria Visconte, PhD1*, Kevin R. Kelly, MD, PhD2, Steffan T. Nawrocki, Ph.D.3, Yingchun Han, MD1*, Hetty E. Carraway, MD, MBA4, Anjali S. Advani, MD4, Jaroslaw P. Maciejewski, MD, Ph.D.1, Heesun J Rogers, MD, PhD5*, Mikkael A. Sekeres, MD, MS4 and Jennifer S. Carew, PhD1

1Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2University of Southern California Keck School of Medicine, Los Angeles, CA
3CTRC Institute for Drug Development, University of Texas Health Science Center at San Antonio, San Antonio, TX
4Leukemia Program, Cleveland Clinic, Cleveland, OH
5Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH

Ana María Hurtado1*, Gines Luengo-Gil1*, Laura Palomo, MSc2*, Eva Lumbreras3*, Eva Caparrós1*, Tzu Hua Chen-Liang1*, Bartlomiej Przychodzen, MSc4*, Maria Luz Amigo1*, María Díez-Campelo, MD, PhD3*, Lurdes Zamora, PhD2*, Francisco José Ortuño1*, Raul Teruel Montoya, PhD1, Jaroslaw P. Maciejewski, MD, Ph.D.5, Consuelo Del Cañizo, MD, PhD3, Francesc Sole, PhD6, Francisca Ferrer-Marin1* and Andres Jerez1*

1Hematology and Medical Oncology Department, Hospital Morales Meseguer. Centro Regional de Hemodonación. Universidad de Murcia. IMIB, MURCIA, Spain
2MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
3Servicio de Hematología, Centro de Investigación del Cáncer, IBSAL (Instituto de Biomedicina de Salamanca) y BMCC, Universidad de Salamanca, Salamanca, Spain
4Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
5Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Josep Carreras Leukaemia Research Institute, Barcelona, Spain

Ayana Kon, MD, Ph.D.1*, Satoshi Yamazaki, PhD2*, Yasunori Ota, MD, PhD3*, Keisuke Kataoka, MD, Ph.D.1*, Yusuke Shiozawa, MD1*, Maiko Morita, MS2*, Tetsuichi Yoshizato, MD1*, Masashi Sanada, MD, Ph.D.4*, Kenichi Yoshida, MD, Ph.D.1*, Manabu Nakayama, PhD5*, Haruhiko Koseki, PhD6*, Hiromitsu Nakauchi, MD, PhD2,7 and Seishi Ogawa, MD, Ph.D.1

1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
3Department of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
4Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
5Laboratory of Medical Genomics, Department of Human Genome Research, Kazusa DNA Research Institute, Chiba, Japan
6Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
7Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA

Yayoi Shikama, MD, PhD1*, Meiwan Cao, MD2*, Tomoyuki Ono2*, Michiko Anzai2*, Hideyoshi Noji, MD, PhD3*, Xiaomin Feng, MD, PhD2*, Hideo Kimura, MD, PhD4*, Kazuei Ogawa, MD, PhD3*, Kazuhiko Ikeda, MD, PhD3, Yasuchika Takeishi, MD, PhD3* and Junko Kimura, MD, PhD2*

1Center for Medical Education and Career Development, Fukushima Medical University, Fukushima, Japan
2Department of Pharmacology, Fukushima Medical University, Fukushima, Japan
3Department of Cardiology and Hematology, Fukushima Medical University, Fukushima, Japan
4Department of Hematology, Kita-Fukushima Medical Center, Date, Japan

Wenhui Shi1*, Feng Xu2*, Chunkang Chang, MD, PhD3* and Xiao Li, MD, PhD3

1Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
2Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
3Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Eiju Negoro, MD, PhD1*, Naoko Hosono, MD, PhD.2*, Wenyi Shen, MD3*, Tetsuichi Yoshizato, MD4*, Bhumika J. Patel1*, Cassandra Hirsh, BSc5*, Bartlomiej Przychodzen, MSc1*, Michael J. Clemente1*, Reda Z. Mahfouz, MD/PhD1, Aleksandra Wodnar-Filipowicz, PhD6*, Hideki Makishima, MD, Ph.D.4, Seishi Ogawa, MD, Ph.D.4, Mikkael A. Sekeres, MD, MS7 and Jaroslaw P. Maciejewski, MD, Ph.D.5

1Department of Translational Hematology and Oncology Research, Taussing Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Hematology and Oncology, University of Fukui, Fukui, Japan
3The First Affilliated Hospitla of Nanjing Medical University, Nanjing, China
4Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
5Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6University Hospital Basel, Basel, Switzerland
7Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

Cara Lunn Shirai, PhD1*, Manorama Tripathi, Ph.D.2*, James N Ley2*, Matthew Ndonwi, PhD3*, Brian S White, PhD4*, Roberto Tapia2*, Borja Saez, PhD5, Amy Bertino, Ph.D.6*, Jin Shao7*, Sanghyun Kim8, Thomas R Webb, Ph.D.9*, Timothy A. Graubert, MD10 and Matthew J. Walter, MD7

1Washington University in St. Louis, Saint Louis, MO
2Washington University in St. Louis, St. Louis, MO
3Oncology/Stem Cell Biology, Washington University School of Medicine, St. Louis, MO
4Washington University School of Medicine, Saint Louis, MO
5Department of Stem Cell and Regenerative Biology, Harvard University. Center for Regenerative Medicine, Massachusetts General Hospital. Harvard Stem Cell Institute, Cambridge, MA
6Massachusetts General Hospital, Boston, MA
7Division of Oncology, Washington University School of Medicine, St. Louis, MO
8Washington University In St. Louis, Saint Louis, MO
9SRI International, Menlo Park, CA
10Massachusetts General Hospital / Harvard Medical School, Boston, MA

Eric J. Duncavage, MD1, Jennifer O'Brien, MD, PhD1*, Kiran R. Vij, MD2, Chris A Miller, PhD3*, Jin Shao2*, Meagan A. Jacoby, MD, PhD2, Robert S. Fulton, PhD4*, Sharon Heath2*, Megan Janke2, Catrina C. Fronick3*, Michelle O'Laughlin3*, Richard K Wilson, PhD5*, Timothy J. Ley, MD2 and Matthew J. Walter, MD2

1Department of Pathology and Immunology, Washington University in St. Louis, Saint Louis, MO
2Department of Medicine, Division of Oncology, Washington University in St. Louis, Saint Louis, MO
3McDonnell Genome Institute, Washington University in St. Louis, Saint Louis, MO
4McDonnell Genome Institute, Washington University, St Louis, MO
5Washington University School of Medicine, Saint Louis, MO

Christopher Felix Krombholz1,2*, Angelina Meier1*, Konrad Aumann3*, Silvia Fluhr1,4*, Matthias Kollek1,2*, Daniel B Lipka5*, Christoph Plass5,6*, Tania Witte5*, Charlotte Niemeyer1,6, Miriam Erlacher1* and Christian Flotho1,6*

1Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany
2Faculty of Biology, University of Freiburg, Freiburg, Germany
3Department of Pathology, University Medical Center, Freiburg, Germany
4Hermann Staudinger Graduate School, University of Freiburg, Freiburg, Germany
5Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany
6German Cancer Consortium, Heidelberg, Germany

Manja Meggendorfer, PhD*, Claudia Haferlach, MD, Wolfgang Kern, MD, Susanne Schnittger, PhD and Torsten Haferlach

MLL Munich Leukemia Laboratory, Munich, Germany

Demi de Winter1*, Marry M van den Heuvel-Eibrink, MD, PhD2,3*, Vincent H.J. van der Velden, PhD4*, Anton W. Langerak5*, Jacques J.M. Dongen1*, Michael Dworzak, MD6*, Barbara De Moerloose, MD, PhD7*, Jan Starý, MD8*, Charlotte M Niemeyer, MD, PhD9, Franco Locatelli, MD10, Henrik Hasle, MD11, Markus Schmugge, MD12, C. Michel Zwaan, MD, PhD13 and Rob Pieters, MD, PhD14,15

1Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
2Department of Pediatric Oncology, Princess Maxima Center for Paediatric Oncology, Utrecht, Netherlands
3Department of Paediatric Oncology/Hematology, Erasmus MC-Sophia’s Children’s Hospital, Rotterdam, Netherlands
4Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
5Department of Immunology, Erasmus MC Rotterdam, Rotterdam, Netherlands
6Department of Pediatrics, Medical University of Vienna, St. Anna Children's Hospital and Children’s Cancer Research Institute, Vienna, Austria
7Department of Pediatrics, Ghent University, Ghent, Belgium
8Department of Pediatric Hematology and Oncology, Charles University and Univ Hospital Motol, Prague, Czech Republic
9Universitaets-Kinderklinik, Freiburg, Germany
10Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
11Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
12Haematology, University Children's Hospital Zurich, Zurich, Switzerland
13Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's hospital, Rotterdam, Netherlands
14Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
15Department of Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands

Yan Ma, MD1*, Lily Remsing Rix1*, Qing Zhang, MD1*, Maria E. Balasis1*, Rami S. Komrokji, MD1, Uwe Rix, PhD1*, Alan F. List, MD2 and Eric Padron, MD1

1H. Lee Moffitt Cancer Center, Tampa, FL
2Department of Hematologic Malignancies, Moffitt Cancer Center and Research Institute, Tampa, FL

Syed A Mian, BSc, M.Phil1*, Austin G. Kulasekararaj, MBBS, MD, MRCP, FRCPath2*, Aytug Kizilors, PhD3,4*, Kathy L McGraw, Ph.D.5, Shahram Kordasti, MD, PhD1,6*, Stephan Menzel, PhD7*, Alexander e Smith, PhD1*, Pilar Perezabellan, MSc1*, David Sallman, M.D.8, Alan F. List, MD9,10 and Ghulam J Mufti, FRCP, FRCPath11

1Department of Haematological Medicine, King's College London, London, United Kingdom
2Department of Haematological Medicine, Kings College Hospital NHS Foundation Trust, London, United Kingdom
3Haematology, King's College London, London, United Kingdom
4Haematology, Laboratory for Molecular Haemato-Oncology, King's College Hospital NHS Foundation Trust/King's College London, London, United Kingdom
5H Lee Moffitt Cancer Center & Research Institute, Tampa, FL
6Haematological Medicine, King's College Hospital, London, United Kingdom
7Molecular Haematology, Kings College London, London, United Kingdom
8Dept. of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
9Department of Hematologic Malignancies, Moffitt Cancer Center and Research Institute, Tampa, FL
10Dept. of Oncologic Sciences, University of South Florida, Morsani College of Medicine, Tampa, FL
11Department of Haematological Medicine, King’s College London, London, United Kingdom

Feng Xu1*, Chunkang Chang, MD, PhD2*, Wenhui Shi3* and Xiao Li, MD, PhD2

1Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
2Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
3Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China

*signifies non-member of ASH